Doubts and concerns about COVID-19 uncertainties on imaging data, clinical score, and outcomes.


Journal

BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563

Informations de publication

Date de publication:
25 Nov 2023
Historique:
received: 10 08 2023
accepted: 15 11 2023
medline: 27 11 2023
pubmed: 26 11 2023
entrez: 25 11 2023
Statut: epublish

Résumé

COVID-19 is a pandemic disease affecting predominantly the respiratory apparatus with clinical manifestations ranging from asymptomatic to respiratory failure. Chest CT is a crucial tool in diagnosing and evaluating the severity of pulmonary involvement through dedicated scoring systems. Nonetheless, many questions regarding the relationship of radiologic and clinical features of the disease have emerged in multidisciplinary meetings. The aim of this retrospective study was to explore such relationship throughout an innovative and alternative approach. This study included 550 patients (range 25-98 years; 354 males, mean age 66.1; 196 females, mean age 70.9) hospitalized for COVID-19 with available radiological and clinical data between 1 March 2021 and 30 April 2022. Radiological data included CO-RADS, chest CT score, dominant pattern, and typical/atypical findings detected on CT examinations. Clinical data included clinical score and outcome. The relationship between such features was investigated through the development of the main four frequently asked questions summarizing the many issues arisen in multidisciplinary meetings, as follows 1) CO-RADS, chest CT score, clinical score, and outcomes; 2) the involvement of a specific lung lobe and outcomes; 3) dominant pattern/distribution and severity score for the same chest CT score; 4) additional factors and outcomes. 1) If CT was suggestive for COVID, a strong correlation between CT/clinical score and prognosis was found; 2) Middle lobe CT involvement was an unfavorable prognostic criterion; 3) If CT score < 50%, the pattern was not influential, whereas if CT score > 50%, crazy paving as dominant pattern leaded to a 15% increased death rate, stacked up against other patterns, thus almost doubling it; 4) Additional factors usually did not matter, but lymph-nodes and pleural effusion worsened prognosis. This study outlined those radiological features of COVID-19 most relevant towards disease severity and outcome with an innovative approach.

Sections du résumé

BACKGROUND BACKGROUND
COVID-19 is a pandemic disease affecting predominantly the respiratory apparatus with clinical manifestations ranging from asymptomatic to respiratory failure. Chest CT is a crucial tool in diagnosing and evaluating the severity of pulmonary involvement through dedicated scoring systems. Nonetheless, many questions regarding the relationship of radiologic and clinical features of the disease have emerged in multidisciplinary meetings. The aim of this retrospective study was to explore such relationship throughout an innovative and alternative approach.
MATERIALS AND METHODS METHODS
This study included 550 patients (range 25-98 years; 354 males, mean age 66.1; 196 females, mean age 70.9) hospitalized for COVID-19 with available radiological and clinical data between 1 March 2021 and 30 April 2022. Radiological data included CO-RADS, chest CT score, dominant pattern, and typical/atypical findings detected on CT examinations. Clinical data included clinical score and outcome. The relationship between such features was investigated through the development of the main four frequently asked questions summarizing the many issues arisen in multidisciplinary meetings, as follows 1) CO-RADS, chest CT score, clinical score, and outcomes; 2) the involvement of a specific lung lobe and outcomes; 3) dominant pattern/distribution and severity score for the same chest CT score; 4) additional factors and outcomes.
RESULTS RESULTS
1) If CT was suggestive for COVID, a strong correlation between CT/clinical score and prognosis was found; 2) Middle lobe CT involvement was an unfavorable prognostic criterion; 3) If CT score < 50%, the pattern was not influential, whereas if CT score > 50%, crazy paving as dominant pattern leaded to a 15% increased death rate, stacked up against other patterns, thus almost doubling it; 4) Additional factors usually did not matter, but lymph-nodes and pleural effusion worsened prognosis.
CONCLUSIONS CONCLUSIONS
This study outlined those radiological features of COVID-19 most relevant towards disease severity and outcome with an innovative approach.

Identifiants

pubmed: 38007479
doi: 10.1186/s12890-023-02763-3
pii: 10.1186/s12890-023-02763-3
pmc: PMC10675953
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

472

Informations de copyright

© 2023. The Author(s).

Références

Acta Radiol. 2022 Mar;63(3):291-310
pubmed: 33631941
BMC Pulm Med. 2020 May 7;20(1):129
pubmed: 32381057
Invest Radiol. 2020 Jun;55(6):327-331
pubmed: 32118615
Radiology. 2020 Apr;295(1):16-17
pubmed: 32017662
Radiology. 2020 Jun;295(3):200463
pubmed: 32077789
Eur Radiol. 2022 May;32(5):3501-3512
pubmed: 35031841
Radiol Cardiothorac Imaging. 2021 Jan 14;3(1):e200510
pubmed: 33778660
Eur Radiol. 2020 Oct;30(10):5470-5478
pubmed: 32394279
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
Eur Radiol. 2020 Aug;30(8):4407-4416
pubmed: 32215691
Radiology. 2008 Mar;246(3):697-722
pubmed: 18195376
J Pers Med. 2021 Apr 14;11(4):
pubmed: 33919882
J Clin Imaging Sci. 2021 Feb 15;11:9
pubmed: 33767901
Rheumatology (Oxford). 2022 Apr 11;61(4):1600-1609
pubmed: 34320649
J Cardiovasc Echogr. 2020 Oct;30(Suppl 2):S25-S30
pubmed: 33489733
Eur Radiol. 2020 Nov;30(11):6129-6138
pubmed: 32474632
Radiology. 2020 Aug;296(2):E97-E104
pubmed: 32339082
Pol J Radiol. 2020 Jul 17;85:e361-e368
pubmed: 32817769
Eur Radiol Exp. 2023 Apr 10;7(1):18
pubmed: 37032383
Insights Imaging. 2020 Nov 23;11(1):118
pubmed: 33226521
Lancet Reg Health West Pac. 2022 May 30;25:100486
pubmed: 35655473
Eur Radiol. 2020 Dec;30(12):6808-6817
pubmed: 32623505
Radiol Med. 2020 Jul;125(7):636-646
pubmed: 32500509
Radiol Cardiothorac Imaging. 2020 Mar 30;2(2):e200047
pubmed: 33778560
Eur Radiol. 2020 Oct;30(10):5463-5469
pubmed: 32399710
Radiology. 2020 Aug;296(2):E55-E64
pubmed: 32191587
Radiology. 2020 Apr;295(1):210-217
pubmed: 32027573
J Med Virol. 2021 Mar;93(3):1449-1458
pubmed: 32790106
Clin Imaging. 2021 Feb;70:61-66
pubmed: 33125986
Radiology. 2020 Jun;295(3):715-721
pubmed: 32053470
Eur J Radiol. 2020 Oct;131:109256
pubmed: 32919265
Chest. 2020 Jul;158(1):106-116
pubmed: 32275978

Auteurs

Cosimo Nardi (C)

Department of Experimental and Clinical Biomedical Sciences, Radiodiagnostic Unit n. 2, University of Florence-Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Andrea Magnini (A)

Department of Experimental and Clinical Biomedical Sciences, Radiodiagnostic Unit n. 2, University of Florence-Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Linda Calistri (L)

Department of Experimental and Clinical Biomedical Sciences, Radiodiagnostic Unit n. 2, University of Florence-Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Edoardo Cavigli (E)

Department of Radiology, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Anna Julie Peired (AJ)

Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Largo Brambilla 3, 50134, Florence, Italy.

Vieri Rastrelli (V)

Department of Experimental and Clinical Biomedical Sciences, Radiodiagnostic Unit n. 2, University of Florence-Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Edoardo Carlesi (E)

Neuroradiology Unit, Department of Radiology, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Giulia Zantonelli (G)

Department of Experimental and Clinical Biomedical Sciences, Radiodiagnostic Unit n. 2, University of Florence-Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Olga Smorchkova (O)

Department of Experimental and Clinical Biomedical Sciences, Radiodiagnostic Unit n. 2, University of Florence-Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Lorenzo Cinci (L)

Department of Experimental and Clinical Biomedical Sciences, Radiodiagnostic Unit n. 2, University of Florence-Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Martina Orlandi (M)

Department of Experimental and Clinical Medicine, Division of Rheumatology, Careggi University Hospital, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.

Nicholas Landini (N)

Department of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I Hospital, "Sapienza" Rome University, Rome, Italy.

Edoardo Berillo (E)

Department of Clinical and Experimental Medicine, Interventional Pulmonology Unit, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Chiara Lorini (C)

Department of Health Sciences, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.

Jessica Mencarini (J)

Department of Experimental and Clinical Medicine, Infectious and Tropical Diseases Unit, Careggi University Hospital, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.

Maria Grazia Colao (MG)

Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.
Clinical Microbiology and Virology Unit, Florence Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Leonardo Gori (L)

Department of Clinical and Experimental Medicine, Interventional Pulmonology Unit, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Valentina Luzzi (V)

Department of Clinical and Experimental Medicine, Interventional Pulmonology Unit, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Chiara Lazzeri (C)

Intensive Care Unit and Regional ECMO Referral Centre, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134, Florence, Italy.

Elisa Cipriani (E)

Intensive Care Unit and Regional ECMO Referral Centre, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134, Florence, Italy.

Manuela Bonizzoli (M)

Intensive Care Unit and Regional ECMO Referral Centre, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134, Florence, Italy.

Filippo Pieralli (F)

Intermediate Care Unit, University Hospital Careggi, Largo Brambilla 3, 50134, Florence, Italy.

Carlo Nozzoli (C)

Internal Medicine Unit 1, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Alessandro Morettini (A)

Internal Medicine Unit 2, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Federico Lavorini (F)

Department of Experimental and Clinical Medicine, Division of Pulmonology, Careggi University Hospital, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.

Alessandro Bartoloni (A)

Department of Experimental and Clinical Medicine, Infectious and Tropical Diseases Unit, Careggi University Hospital, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.

Gian Maria Rossolini (GM)

Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.
Clinical Microbiology and Virology Unit, Florence Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Marco Matucci-Cerinic (M)

Department of Experimental and Clinical Medicine, Division of Rheumatology, Careggi University Hospital, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.

Sara Tomassetti (S)

Department of Clinical and Experimental Medicine, Interventional Pulmonology Unit, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Stefano Colagrande (S)

Department of Experimental and Clinical Biomedical Sciences, Radiodiagnostic Unit n. 2, University of Florence-Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy. stefano.colagrande@unifi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH